Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oncogene Proteins, Fusion | 5 | 2021 | 1581 | 0.800 |
Why?
|
| Cytidine Deaminase | 1 | 2023 | 252 | 0.780 |
Why?
|
| Carbazoles | 2 | 2021 | 226 | 0.660 |
Why?
|
| Lung Neoplasms | 10 | 2023 | 13102 | 0.640 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2015 | 1660 | 0.630 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2023 | 5172 | 0.590 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2023 | 5221 | 0.470 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2014 | 101 | 0.460 |
Why?
|
| Piperidines | 2 | 2021 | 1602 | 0.420 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2014 | 1086 | 0.390 |
Why?
|
| Stomach Neoplasms | 5 | 2001 | 1333 | 0.380 |
Why?
|
| Acrylamides | 2 | 2023 | 255 | 0.350 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2023 | 5535 | 0.340 |
Why?
|
| Serine Endopeptidases | 1 | 2014 | 1072 | 0.330 |
Why?
|
| Pyrazoles | 2 | 2016 | 1972 | 0.330 |
Why?
|
| Pyridines | 2 | 2016 | 2825 | 0.300 |
Why?
|
| Cell Cycle Proteins | 5 | 2015 | 3462 | 0.280 |
Why?
|
| Pyrimidines | 3 | 2023 | 2942 | 0.210 |
Why?
|
| Adenocarcinoma | 4 | 2014 | 6364 | 0.180 |
Why?
|
| Genomic Instability | 1 | 2023 | 695 | 0.170 |
Why?
|
| Gastrectomy | 3 | 2001 | 663 | 0.160 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2023 | 594 | 0.160 |
Why?
|
| Aniline Compounds | 2 | 2023 | 986 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2018 | 220 | 0.160 |
Why?
|
| Oligosaccharides | 1 | 1998 | 414 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 11524 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2015 | 57 | 0.140 |
Why?
|
| Thromboxane-A Synthase | 1 | 2015 | 34 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 6386 | 0.140 |
Why?
|
| Mutation | 6 | 2023 | 29786 | 0.130 |
Why?
|
| Indoles | 1 | 2023 | 1839 | 0.130 |
Why?
|
| Receptor, erbB-3 | 1 | 2015 | 142 | 0.130 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 16689 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 390 | 0.110 |
Why?
|
| Janus Kinase 2 | 1 | 2016 | 528 | 0.110 |
Why?
|
| Neoplasm Proteins | 4 | 2000 | 3703 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 1998 | 1602 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 1999 | 975 | 0.100 |
Why?
|
| Sulfones | 1 | 2014 | 437 | 0.100 |
Why?
|
| Hyponatremia | 1 | 2014 | 298 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2023 | 2727 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 13695 | 0.100 |
Why?
|
| Esophageal Neoplasms | 4 | 2001 | 1583 | 0.090 |
Why?
|
| Mice, Nude | 2 | 2015 | 3689 | 0.090 |
Why?
|
| Mesothelioma | 1 | 2015 | 818 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 4 | 2001 | 3616 | 0.080 |
Why?
|
| Cisplatin | 1 | 2014 | 1662 | 0.080 |
Why?
|
| Immunohistochemistry | 6 | 2014 | 11366 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 2649 | 0.080 |
Why?
|
| Colorectal Neoplasms | 4 | 2001 | 6773 | 0.080 |
Why?
|
| Esophagectomy | 2 | 2001 | 447 | 0.070 |
Why?
|
| Prognosis | 8 | 2016 | 29063 | 0.070 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 11031 | 0.070 |
Why?
|
| Iron | 1 | 2015 | 1774 | 0.070 |
Why?
|
| Carcinoma | 1 | 1998 | 2375 | 0.070 |
Why?
|
| Survival Rate | 3 | 2016 | 12788 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2001 | 604 | 0.070 |
Why?
|
| Lymphatic Metastasis | 4 | 2001 | 2924 | 0.060 |
Why?
|
| Middle Aged | 21 | 2021 | 213383 | 0.060 |
Why?
|
| Female | 23 | 2021 | 380194 | 0.060 |
Why?
|
| Humans | 28 | 2023 | 744343 | 0.050 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 57776 | 0.050 |
Why?
|
| Aged | 16 | 2021 | 163280 | 0.050 |
Why?
|
| Male | 21 | 2021 | 350118 | 0.050 |
Why?
|
| Serous Membrane | 1 | 2001 | 28 | 0.050 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2001 | 44 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2000 | 285 | 0.050 |
Why?
|
| Hepatic Veins | 1 | 2001 | 112 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2001 | 2849 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 802 | 0.040 |
Why?
|
| Mucin-1 | 1 | 2023 | 543 | 0.040 |
Why?
|
| Esophagoscopy | 1 | 2000 | 390 | 0.040 |
Why?
|
| Guanidines | 1 | 1999 | 193 | 0.040 |
Why?
|
| Mice | 3 | 2015 | 81183 | 0.040 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 1999 | 162 | 0.040 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 1999 | 83 | 0.040 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 1999 | 179 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2001 | 12245 | 0.040 |
Why?
|
| Hepatectomy | 1 | 2001 | 550 | 0.040 |
Why?
|
| Cell Division | 3 | 2001 | 4568 | 0.040 |
Why?
|
| Leiomyosarcoma | 1 | 2001 | 477 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2000 | 673 | 0.040 |
Why?
|
| Adult | 11 | 2021 | 214055 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2001 | 4034 | 0.040 |
Why?
|
| Animals | 5 | 2016 | 168757 | 0.040 |
Why?
|
| Thyroid Neoplasms | 2 | 2001 | 2282 | 0.040 |
Why?
|
| Glucaric Acid | 1 | 2015 | 10 | 0.030 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2000 | 506 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 39050 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2000 | 547 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1999 | 671 | 0.030 |
Why?
|
| Deoxyguanosine | 1 | 2015 | 84 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 1783 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1999 | 895 | 0.030 |
Why?
|
| Mutation, Missense | 2 | 2001 | 2564 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 2503 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2001 | 1534 | 0.030 |
Why?
|
| Stomach | 1 | 1999 | 697 | 0.030 |
Why?
|
| Liver Neoplasms | 2 | 2001 | 4253 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 1999 | 783 | 0.030 |
Why?
|
| Immune System | 1 | 1999 | 805 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 281 | 0.030 |
Why?
|
| Ferric Compounds | 1 | 2015 | 374 | 0.030 |
Why?
|
| Iron Overload | 1 | 2015 | 242 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2018 | 1364 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 1999 | 1403 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 1792 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2001 | 1703 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2016 | 53288 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2015 | 1901 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 23403 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2001 | 10252 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1999 | 1524 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 1401 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2016 | 2716 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2001 | 1863 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 1276 | 0.020 |
Why?
|
| Drugs, Generic | 1 | 2014 | 421 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 56430 | 0.020 |
Why?
|
| Loss of Heterozygosity | 2 | 2001 | 684 | 0.020 |
Why?
|
| Oxygen | 1 | 2001 | 4189 | 0.020 |
Why?
|
| Cause of Death | 1 | 1999 | 3584 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 4554 | 0.020 |
Why?
|
| Patient Selection | 1 | 2000 | 4215 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2001 | 2214 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 1999 | 323 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 3557 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2015 | 3002 | 0.020 |
Why?
|
| Genes, ras | 2 | 2001 | 690 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 4420 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 2 | 1999 | 573 | 0.020 |
Why?
|
| Prescription Drugs | 1 | 2014 | 595 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2000 | 2020 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2001 | 9648 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 1999 | 595 | 0.020 |
Why?
|
| Odds Ratio | 1 | 1999 | 9849 | 0.020 |
Why?
|
| Proteins | 1 | 2001 | 6103 | 0.020 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 5853 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 8436 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2014 | 6459 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 3768 | 0.020 |
Why?
|
| Apoptosis | 1 | 1999 | 9727 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1998 | 8428 | 0.010 |
Why?
|
| E2F4 Transcription Factor | 1 | 2001 | 36 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2001 | 12208 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1999 | 5256 | 0.010 |
Why?
|
| Postoperative Complications | 2 | 2001 | 15295 | 0.010 |
Why?
|
| S Phase | 1 | 2001 | 423 | 0.010 |
Why?
|
| G1 Phase | 1 | 2001 | 415 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2016 | 10481 | 0.010 |
Why?
|
| Incidence | 1 | 1998 | 20947 | 0.010 |
Why?
|
| Benzamidines | 1 | 1999 | 25 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1998 | 9239 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2001 | 1101 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2014 | 77449 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2001 | 520 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2001 | 528 | 0.010 |
Why?
|
| Transplants | 1 | 2001 | 209 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1999 | 234 | 0.010 |
Why?
|
| Codon | 1 | 2001 | 611 | 0.010 |
Why?
|
| Life Tables | 1 | 1999 | 370 | 0.010 |
Why?
|
| Rats | 1 | 2015 | 24260 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 1999 | 318 | 0.010 |
Why?
|
| Solubility | 1 | 1999 | 1085 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 1999 | 264 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2001 | 1266 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1999 | 297 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2000 | 755 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 1999 | 644 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 2001 | 662 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 1999 | 357 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2001 | 1097 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2018 | 40561 | 0.010 |
Why?
|
| Point Mutation | 1 | 2001 | 1623 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2001 | 1813 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2001 | 2126 | 0.010 |
Why?
|
| Transfection | 1 | 2001 | 5892 | 0.010 |
Why?
|
| Pedigree | 1 | 2001 | 4644 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2001 | 1788 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2000 | 1692 | 0.010 |
Why?
|
| Pancreas | 1 | 1999 | 1686 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1999 | 20822 | 0.010 |
Why?
|
| Reference Values | 1 | 1999 | 4982 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2001 | 5974 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2001 | 2915 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1999 | 2967 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2000 | 2948 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1999 | 4026 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1999 | 8642 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 2001 | 13033 | 0.000 |
Why?
|
| Treatment Outcome | 2 | 2000 | 63114 | 0.000 |
Why?
|
| Disease Progression | 1 | 1999 | 13284 | 0.000 |
Why?
|
| Child | 1 | 2001 | 77709 | 0.000 |
Why?
|
Concepts
(193)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(23)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_